Form 4: Evommune Executive Receives Stock Option Grant

Chief Business & Legal Officer Gregory S. Moss was granted 115,279 stock options in Evommune, Inc.

Summary

• Gregory S. Moss, Chief Business & Legal Officer of Evommune, Inc., received a grant of 115,279 employee stock options.
• The options have an exercise price of $26.77 per share.
• The grant date for these options is April 16, 2026.
• The options expire on April 15, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding executive compensation that does not signal a change in company strategy or financial health.

Positives

• Aligns executive compensation with long-term shareholder value through equity-based incentives.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Future dilution of equity if options are exercised.

Future Outlook

The options vest over a four-year period, with 25% vesting on the first anniversary and the remainder in 36 equal monthly installments, contingent on continued service.

Industry Context

StockSavvy.ai notes that equity grants for C-suite executives in the biotechnology sector are standard practice to ensure leadership retention and alignment with long-term clinical and commercial milestones.

Comparison to Industry Standards

• The four-year vesting schedule is consistent with standard industry practices for executive equity compensation.

Stakeholder Impact

• Minor potential dilution for shareholders upon future exercise of options.

Next Steps

• Vesting of options beginning April 16, 2027.

Key Dates

Keywords

Evommune, EVMN, Form 4, Stock Options, Insider Transaction, Executive Compensation